Paper36085147
Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.
Liu D and 8 others. Cell Discov, 2022. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs. Papers, record 36085147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36085147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81788101 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 2021- I2M-1-022 | Chinese Academy of Medical Sciences (CAMS) | PubMed | ||
| 2021-CAMS-JZ001 | Chinese Academy of Medical Sciences (CAMS) | PubMed | ||
| 2021- I2M-1-062 | Chinese Academy of Medical Sciences (CAMS) | PubMed |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25890286 | Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice. | Part Fibre Toxicol | 2015 | https://conductscience.org/library/papers/25890286 | PubMed |
| 2 | 25655897 | Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. | Sci China Life Sci | 2015 | https://conductscience.org/library/papers/25655897 | PubMed |
| 3 | 35405099 | Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. | Am Heart J | 2022 | https://conductscience.org/library/papers/35405099 | PubMed |
| 4 | 32048163 | Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. | Sci China Life Sci | 2020 | https://conductscience.org/library/papers/32048163 | PubMed |
| 5 | 16007097 | A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. | Nat Med | 2005 | https://conductscience.org/library/papers/16007097 | PubMed |
| 6 | 31433752 | Angiotensin Type 1 Receptor Blockers in Heart Failure. | Curr Drug Targets | 2020 | https://conductscience.org/library/papers/31433752 | PubMed |
| 7 | 25391767 | Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. | Sci Rep | 2014 | https://conductscience.org/library/papers/25391767 | PubMed |
| 8 | 33464336 | Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. | JAMA | 2021 | https://conductscience.org/library/papers/33464336 | PubMed |
| 9 | 34590760 | The inhibitory mechanisms of losartan and vitamin D on amiodarone-induced lung inflammation in rats: Role of mitogen-activated protein kinases/activator protein-1. | J Biochem Mol Toxicol | 2021 | https://conductscience.org/library/papers/34590760 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40868984 | Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40868984 | PubMed |
| 40722848 | Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722848 | PubMed |
| 39599890 | Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. | Viruses | 2024 | https://conductscience.org/library/papers/39599890 | PubMed |
| 38891966 | Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood-Brain Barrier. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38891966 | PubMed |
| 38139391 | Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38139391 | PubMed |
| 37662725 | Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients. | Heliyon | 2023 | https://conductscience.org/library/papers/37662725 | PubMed |
| 37238657 | Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019. | Biomolecules | 2023 | https://conductscience.org/library/papers/37238657 | PubMed |
| 37038324 | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. | Pharmacol Res Perspect | 2023 | https://conductscience.org/library/papers/37038324 | PubMed |
| 36864220 | Green fluorometric strategy for simultaneous determination of the antihypertensive drug telmisartan (A tentative therapeutic for COVID-19) with Nebivolol in human plasma. | Sci Rep | 2023 | https://conductscience.org/library/papers/36864220 | PubMed |
| 36835602 | Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36835602 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 | NCBI Gene |
| AGTR1 | 185 | PubTator's text mining | https://conductscience.org/library/genes/185 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36085147
GET https://conductscience.org/api/papers/v1/36085147/authors